The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinoma.
 
Devalingam Mahalingam
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Eisai; Exelixis; Genentech
Research Funding - Merck KGaA; Oncolytics
 
Siqi Chen
No Relationships to Disclose
 
Ping Xie
No Relationships to Disclose
 
Aparna Kalyan
Honoraria - Samumed
Consulting or Advisory Role - Bristol-Myers Squibb; BTG; Eisai; Exelixis; Ipsen
Speakers' Bureau - Exelixis
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Exelixis
 
Sheetal Mehta Kircher
Stock and Other Ownership Interests - Abbott/AbbVie; Penrose
 
Masha Kocherginsky
Patents, Royalties, Other Intellectual Property - Royalties - co-inventor on Patent 9149485, "Methods and compositions related to glucocorticoid receptor antagonists and breast cancer".
 
Jiahui Xu
No Relationships to Disclose
 
Victoria Maurer
No Relationships to Disclose
 
Pedro Antonio Hermida de Viveiros
No Relationships to Disclose
 
Elena Vagia
No Relationships to Disclose
 
Grey A Wilkinson
Employment - Oncolytics
 
Matthew C. Coffey
Employment - Oncolytics
Leadership - Oncolytics
Stock and Other Ownership Interests - Oncolytics
 
Mary Frances Mulcahy
Research Funding - BTG
 
Al Bowen Benson
Consulting or Advisory Role - American Cancer Society; Array BioPharma; BioNest; Bristol-Myers Squibb; Cancer Expert Now; Decision Resources; Harborside Press; Health Advances; i3 Health; Imedex; Lynx Group; Merck Sharp & Dohme; Merck Sharp & Dohme; Precisca; PrECOG; Research to Practice; Shanghai International Colorectal Cancer Symposium; Springer; The Dedham Group; Total Health Conferencing
Research Funding - Advanced Accelerator Applications (Inst); American College of Radiology (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); ECOG-ACRIN (Inst); Elevar Therapeutics (Inst); Infinity Pharmaceuticals (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); PrECOG (Inst); Rafael Pharmaceuticals (Inst); st pharm (Inst); SynCoreBio (Inst); Taiho Pharmaceutical (Inst); Tyme Inc (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Association of Community Cancer Centers (ACCC); Bristol-Myers Squibb; CancerCare; Lynx Group; Merck Sharp & Dohme; MJH Healthcare Holdings, LLC; NCCN; North American Neuroendocrine Tumor Society; NPAF/PAF
 
Bin Zhang
No Relationships to Disclose